Filing Flows › BeOne Medicines (ONC) › Q3 2026
BeOne Medicines (ONC) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 5, 2026
BeOne Medicines (ONC) reported revenue of $1.9B for the third quarter 2026 (Q3 2026), +34% from a year earlier and +11% from the quarter before. Operating margin was 22.2%, net earnings $385M (20.4% of revenue).
BeOne Medicines, Q3 2026: revenue $1.9B (+34% year over year), operating margin 22.2%, net earnings $385M, operating cash flow $509M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.9B | +11% | +34% |
| Gross profit | $1.7B | +9% | +38% |
| Operating profit | $419M | +29% | +157% |
| Net earnings | $385M | +62% | +208% |
| Operating cash flow | $509M | +10% | +26% |
| Free cash flow | $474M | +9% | +34% |
What changed
Revenue was $1.9B in Q3 2026, up 34% year over year and up 11% from the previous quarter. BRUKINSA was the largest line at 74% of revenue. BRUKINSA added $0.35B year over year (up 34%), 73% of the total change. KYPROLIS declined 24%.
Gross margin was 88.5%, up 2.4 points from Q3 2025. Operating profit was $0.42B, a 22.2% margin (up 10.6 points year over year). Of the extra revenue versus Q3 2025, 54% reached operating profit, above the 12% margin then. Operating expenses grew 19% against revenue growth of 34%. The fastest-growing cost line was Research & development (+26%). Net earnings were $0.38B, up 208% year over year. The effective tax rate was 6.3%.
Operating cash flow was $0.51B (up 26% year over year), 132% of net earnings. Non-cash charges added back $0.06B of depreciation and amortization and $0.13B of share-based compensation. Working capital and other items used $0.07B. Capital expenditures of $0.04B left free cash flow of $0.47B.
Questions
What was BeOne Medicines' revenue in the third quarter 2026?
BeOne Medicines (ONC) reported revenue of $1.9B for the third quarter 2026 (Q3 2026), +34% from a year earlier and +11% from the quarter before.
Was BeOne Medicines profitable in the third quarter 2026?
Operating profit was $419M (22.2% of revenue) and net earnings $385M.
Source: BeOne Medicines 10-Q on SEC EDGAR.